Advertisement
Anocca enters strategic partnership with Shinobi Therapeutics
The two companies have announced a strategic partnership to use Shinobi’s immune evasive iPS-T cell platform with novel candidate TCRs, discovered and validated by Anocca, to develop a new class of off-the-shelf allogeneic TCR engineered iPS-T-cell therapies (TCR-iPS-T) for solid tumors.
“As we prepare to progress our first gene-edited autologous TCR-T product into the clinic, we are excited to partner with Shinobi and work together to develop innovative off-the-shelf TCR-T cell therapies,” says Anocca’s CEO and co-founder, Reagan Jarvis. “Shinobi’s Katana platform has the potential to offer treatment options for most cancer patients when combined with Anocca’s ability to systematically unlock the largely unexploited landscape of TCR-T targets.”
Novel off-the-shelf treatments in solid tumor indications
Shinobi’s ‘Katana’ technology specifically enables the efficient introduction of antigen-targeting TCR and/or CAR constructs into its immune evasive iPS-T cells in a plug-and-play manner, states Anocca. Anocca has developed a deep-tech discovery platform that uses programmable human cells to recreate and manipulate T-cell immunity and deliver libraries of highly specific, clinically deployable TCR candidates for the treatment of solid cancers.
In this joint program, Shinobi and Anocca will work together to produce TCR engineered CD8 abiPS-T-cells against validated cancer targets and deliver pre-clinical proof of concept. A successful outcome will pave the way for the development of novel off-the-shelf treatments in solid tumor indications for the broadest patient populations.
Photo of Reagan Jarvis: Anocca
Published: May 30, 2024
Advertisement